Use intravenous immunoglobulin chronic lymphocytic leukemia brief review Chronic lymphocytic leukemia CLL disorder multiple defects susceptibility infection Hypogammaglobulinemia present patients CLL Intravenous immunoglobulin IVIG supplementation mg/kg body weeks bacterial infections patients ongoing study doses mg/kg/mo mg/kg/mo patients writing rate infection treatment groups different substantial loss protection bacterial infection lower-dose group likely dose effective standard therapy cost savings substantial 